Specific mutated BRCA regions confer different risks of breast, ovarian cancers
the ONA take:
According to a new study published in JAMA, researchers at the The Basser Center for BRCA, the Perelman School of Medicine at the University of Pennsylvania, and the Abramson Cancer Cancer Center, have found specific BRCA mutations confer higher risks of breast cancer, while other BRCA mutations confer higher risks of ovarian cancer.
For the study, researchers evaluated cancer diagnoses for 19,581 carriers of BRCA1 mutations and 11,900 carriers of BRCA2 mutations. Results showed that women who carry a certain subset of BRCA mutations typically found in the Ashkenazi Jewish population have a 69% risk of breast cancer and a 26% ovarian cancer.
Previous research showed that a woman with a BRCA1 mutations automatically has a 59% risk of breast cancer and a 34% risk of ovarian cancer.
The findings suggest that there are certain regions on the BRCA1 and BRCA2 genes that, when mutated, increase a woman's risk for breast cancer, while other mutated regions increase a woman's risk for ovarian cancer.
Specific BRCA mutations confer higher risks of breast cancer, while other BRCA mutations confer higher risks of ovarian cancer.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
- Urine Drug Testing Policy Can Assist Opioid Treatment Decisions
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|